Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients

被引:0
|
作者
Elmer, GW
McFarland, LV
Surawicz, CM
Danko, L
Greenberg, RN
机构
[1] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
[2] Biocodex Inc, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA
[4] Univ Kentucky, Dept Med, Div Infect Dis, Lexington, KY 40506 USA
[5] Lexington Vet Affairs Med Ctr, Lexington, KY USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Despite recent interest in therapeutic microorganisms taken orally, little is known about the pharmacodynamics of these agents in a target population of patients with disease. The present study reports the stool concentrations of Saccharomyces boulardii in a patient population with Clostridium difficile disease (CDD) and correlates stool concentrations with efficacy. Methods: Patients with recurrent CDD all received a 10-day standard antibiotic regimen together with 28 days of S. boulardii or placebo. Stool samples were collected from patients at various time points and assayed for S. boulardii. Results: The mean concentration of S. boulardii of patients who recurred was 2.5 x 10(4) CFU/g compared to 1 x 10(6) CFU/g in patients that did not recur (P=0.02). Patients with low yeast concentrations in their stools (< 10(4)/g) recurred more often (14/15, 93%) compared with patients with higher levels (19/35, 54%, P=0.007). Clearance of S. boulardii was rapid; only 4% had positive stools 3 days after stopping dosing. Conclusions: After chronic dosing of S. boulardii, patients with low stool concentrations had a higher likelihood of recurrence of CDD. Stool concentrations were also lower during periods of diarrhoea. These results show the importance of characterizing the dynamics of a therapeutic microorganism in patients with disease, as kinetic studies in healthy volunteers may not give a true reflection of the disturbed microecology in the disease state.
引用
收藏
页码:1663 / 1668
页数:6
相关论文
共 50 条
  • [41] Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat
    Izadnia, F
    Wong, CT
    Kocoshis, SA
    DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (09) : 2055 - 2060
  • [42] Brewer's Yeast and Saccharomyces boulardii Both Attenuate Clostridium difficile-Induced Colonic Secretion in the Rat
    Fariba Izadnia
    Catarina Tse Wong
    Samuel A. Kocoshis
    Digestive Diseases and Sciences, 1998, 43 : 2055 - 2060
  • [43] Recurrent Clostridium difficile diarrhoea
    Kyne, L
    Kelly, CP
    GUT, 2001, 49 (01) : 152 - 153
  • [44] Therapy for recurrent Clostridium difficile
    不详
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (06) : U4 - U4
  • [45] Recurrent Clostridium difficile enterocolitis
    Bergamin, B
    Hess, T
    Jost, R
    Ballmer, PE
    Imoberdorf, R
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 2000, 130 (44) : 1681 - 1684
  • [46] Humanized microbiota mice as a model of recurrent Clostridium difficile disease
    James Collins
    Jennifer M. Auchtung
    Laura Schaefer
    Kathryn A. Eaton
    Robert A. Britton
    Microbiome, 3
  • [47] Humanized microbiota mice as a model of recurrent Clostridium difficile disease
    Collins, James
    Auchtung, Jennifer M.
    Schaefer, Laura
    Eaton, Kathryn A.
    Britton, Robert A.
    MICROBIOME, 2015, 3 : 35
  • [48] Diagnostic and treatment delays in recurrent Clostridium difficile -: associated disease
    Scheurer, Danielle
    JOURNAL OF HOSPITAL MEDICINE, 2008, 3 (02) : 156 - 159
  • [49] Saccharomyces boulardii protease inhibits Clostridium difficile toxin A and B-induced effects in human colonic mucosa.
    Castagliuolo, I
    Valenick, L
    Riegler, M
    LaMont, JT
    Pothoulakis, C
    GASTROENTEROLOGY, 1998, 114 (04) : A948 - A949
  • [50] EFFECT OF ORAL SACCHAROMYCES-BOULARDII TREATMENT ON THE ACTIVITY OF CLOSTRIDIUM-DIFFICILE TOXINS IN MOUSE DIGESTIVE-TRACT
    CORTHIER, G
    LUCAS, F
    JOUVERT, S
    CASTEX, F
    TOXICON, 1992, 30 (12) : 1583 - 1589